Catalyst down but not out on second trial failure of cocaine addiction drug
This article was originally published in Scrip
Catalyst Pharmaceutical Partners lost 65.5% of its market value on 8 November based on the not particularly surprising news that CPP-109 (vigabatrin), its drug therapy for cocaine addiction, did not meet primary or secondary endpoints in a Phase IIb clinical trial.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.